Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Entereg Fails Phase III Trial; Adolor/GSK To Re-Examine Placebo Effect

This article was originally published in The Pink Sheet Daily

Executive Summary

Disappointing results throw into question the timing of sNDA submission.

You may also be interested in...



Entereg RiskMAP’s Ability To Prevent Heart Attacks Gets Advisory Panel Review

FDA questions the risk-management plan proposed by GlaxoSmithKline/Adolor to address myocardial infarctions reported in Phase III studies for alvimopan in GI indication.

Entereg RiskMAP’s Ability To Prevent Heart Attacks Gets Advisory Panel Review

FDA questions the risk-management plan proposed by GlaxoSmithKline/Adolor to address myocardial infarctions reported in Phase III studies for alvimopan in GI indication.

GSK/Adolor To Begin New Phase III Entereg Trial In Opioid-Induced Bowel Dysfunction

Companies also anticipate submitting “complete response” to FDA for postoperative ileus indication in second quarter.

Related Content

Topics

UsernamePublicRestriction

Register

LL1130421

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel